UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    Form 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

                                  June 3, 2005
                Date of Report (Date of earliest event reported)

                    KIWA BIO-TECH PRODUCTS GROUP CORPORATION
             (Exact name of registrant as specified in its charter)

          Delaware                       000-33167             84-0448400
(State or other jurisdiction            (Commission         (I.R.S. Employer
       of incorporation)                File Number)        Identification No.)

      17700 Castleton Street, Suite 589, City of Industry, California 91748

                    (Address of principal executive offices)

                    Issuer's telephone number: (626) 964-3232

              (Registrant's telephone number, including area code)

                                       N/A
          (Former Name or Former Address, if changed since Last Report)

      Check the  appropriate  box below if the Form 8-K  filing is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

      |_| Written  communications  pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)

      |_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)

      |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))

      |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))


                                       1
<PAGE>

Item 2.01 Entry into a Material Definitive Agreement.

On May 30, 2005 we entered into separate loan  agreements  with two  individuals
unaffiliated  with the  company in the  amount of  U.S.$150,000  each  ($300,000
principal total). The loans were partially funded and became binding obligations
of the company on June 3, 2005. Interest on the notes is 12% per annum,  payable
monthly.  The notes  mature in three months which we may extend to six months at
our election.

Our chief Executive  Officer,  Mr. Wei Li,  personally  guaranteed the notes for
US$300,000  total and the notes are secured by our assets.  We have the right in
our sole discretion to redeem the notes in whole or in part for 125% of the face
amount plus accrued and unpaid interest.

Pursuant to the notes we issued  each of the lenders a warrant for the  purchase
of up to 750,000  shares of our common  stock.  The  warrants  must be exercised
within 24 months of being issued and the exercise price is based on the price of
our common stock on the date of exercise.

Proceeds from the notes were used to retire the 10% Loan  described in Item 2.02
below.

Item 2.02 Entry into a Material Definitive Agreement.

On September 23, 2004 we entered into a convertible  loan agreement for $350,000
with interest at 10% per annum (the "10% Loan"), and issued 1,050,000 detachable
warrants. The lender is an unrelated party located in the United States. The 10%
Loan was  initially  due on March  23,  2005,  but the final  maturity  date was
subsequently  extended by agreement to April 21, 2005. The Company did not repay
the 10% Loan by the  extended  maturity  date  and the  lenders  declared  it in
default.  Prior  to June  8we made  payments  to the  lender  in the  amount  of
$359,991,  which  included  penalty  interest.  On June 8 we  signed  a  Payment
Acknowledgment and Release with the lender in which the lender acknowledged full
satisfaction  of the 10% Loan and released the company from all liability  under
the 10% Loan.

Proceeds  from the notes  described in Item 2.01 of this Report on 8-K were used
to retire the 10% Loan.


                                       2
<PAGE>

                                    SIGNATURE

      Pursuant to the  requirements  of the Securities  Exchange Act of 1934, as
amended,  the  registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.

/S/ LI WEI                         June  9, 2005 Chairman of Board of Directors
                                   and Chief Executive Officer
------------------
Wei Li


                                       3
{"company-data": {"conformed-name": "KIWA BIO-TECH PRODUCTS GROUP CORP", "cik": "0001159275", "assigned-sic": "8731", "irs-number": "870448400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-33167", "film-number": "05888656"}, "business-address": {"street1": "17700 CASTLETON STREET", "street2": "SUITE 589", "city": "CITY OF INDUSTRY", "state": "CA", "zip": "91748", "phone": "(626) 964-3232"}, "mail-address": {"street1": "17700 CASTLETON STREET", "street2": "SUITE 589", "city": "CITY OF INDUSTRY", "state": "CA", "zip": "91748"}, "former-company": {"former-conformed-name": "TINTIC GOLD MINING  CO", "date-changed": "20010918"}}
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    Form 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

                                  June 3, 2005
                Date of Report (Date of earliest event reported)

                    KIWA BIO-TECH PRODUCTS GROUP CORPORATION
             (Exact name of registrant as specified in its charter)

          Delaware                       000-33167             84-0448400
(State or other jurisdiction            (Commission         (I.R.S. Employer
       of incorporation)                File Number)        Identification No.)

      17700 Castleton Street, Suite 589, City of Industry, California 91748

                    (Address of principal executive offices)

                    Issuer's telephone number: (626) 964-3232

              (Registrant's telephone number, including area code)

                                       N/A
          (Former Name or Former Address, if changed since Last Report)

      Check the  appropriate  box below if the Form 8-K  filing is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

      |_| Written  communications  pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)

      |_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)

      |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))

      |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))

                                       1
Item 2.01 Entry into a Material Definitive Agreement.

On May 30, 2005 we entered into separate loan  agreements  with two  individuals
unaffiliated  with the  company in the  amount of  U.S.$150,000  each  ($300,000
principal total). The loans were partially funded and became binding obligations
of the company on June 3, 2005. Interest on the notes is 12% per annum,  payable
monthly.  The notes  mature in three months which we may extend to six months at
our election.

Our chief Executive  Officer,  Mr. Wei Li,  personally  guaranteed the notes for
US$300,000  total and the notes are secured by our assets.  We have the right in
our sole discretion to redeem the notes in whole or in part for 125% of the face
amount plus accrued and unpaid interest.

Pursuant to the notes we issued  each of the lenders a warrant for the  purchase
of up to 750,000  shares of our common  stock.  The  warrants  must be exercised
within 24 months of being issued and the exercise price is based on the price of
our common stock on the date of exercise.

Proceeds from the notes were used to retire the 10% Loan  described in Item 2.02
below.

Item 2.02 Entry into a Material Definitive Agreement.

On September 23, 2004 we entered into a convertible  loan agreement for $350,000
with interest at 10% per annum (the "10% Loan"), and issued 1,050,000 detachable
warrants. The lender is an unrelated party located in the United States. The 10%
Loan was  initially  due on March  23,  2005,  but the final  maturity  date was
subsequently  extended by agreement to April 21, 2005. The Company did not repay
the 10% Loan by the  extended  maturity  date  and the  lenders  declared  it in
default.  Prior  to June  8we made  payments  to the  lender  in the  amount  of
$359,991,  which  included  penalty  interest.  On June 8 we  signed  a  Payment
Acknowledgment and Release with the lender in which the lender acknowledged full
satisfaction  of the 10% Loan and released the company from all liability  under
the 10% Loan.

Proceeds  from the notes  described in Item 2.01 of this Report on 8-K were used
to retire the 10% Loan.

                                       2
SIGNATURE

      Pursuant to the  requirements  of the Securities  Exchange Act of 1934, as
amended,  the  registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.

/S/ LI WEI                         June  9, 2005 Chairman of Board of Directors
                                   and Chief Executive Officer
------------------
Wei Li

                                       3